According to the speaker, what distinguishes elritercept from other anemia-directed agents in myelofibrosis, based on the RESTORE trial?
It improves hemoglobin by acting only on the erythroid lineage, with no effect on platelets.
It often produces a dual response, improving both hemoglobin and platelet counts, likely by rebalancing the bone marrow microenvironment through modulation of TGF-β superfamily signaling (activin A and B).
It improves platelet counts but has no meaningful effect on anemia, so it is best suited to thrombocytopenic patients.